Xvivo Perfusion

XVIVO recorded net revenue of SEK 239m in the second quarter, above the analyst estimate of SEK 235.68m. Revenue rose 34% year-on-year (organic +36%), driven by the thorax segment (+53% in local currency) and the abdominal segment (+26%), while service revenue declined 25%. The company reported a net profit of SEK 16.30m (earnings per share SEK 0.52) and an operating profit of SEK 25m, and sees growth potential from increasing adoption of its technologies. » Więcej na de.investing.com

Xvivo Perfusion reports net sales of SEK 586m for Q3 2025 and organic growth of 6% (excluding heart study). The abdomen segment posts a record organic growth of 47%, while the thoracic segment shows a revenue decline of 12%. Operating cash flow was SEK 21m, liquidity stands at SEK 280m; the share rose 1.28% after the earnings call. Management is focused on CE approval of the heart technology, expanding US services and an FDA submission for the heart technology by Q2 2026. » Więcej na de.investing.com

XVivo reported net revenue of SEK 178 million for the second quarter of 2025 and negative organic growth of 11%. Gross margin remained stable at 74%, and adjusted EBITDA was 13%. The company has initiated a cost-reduction and restructuring program but maintains its strategic focus on heart and liver technologies as well as planned product launches and studies. Negative currency effects and a customer inventory reduction weighed on results; the share price fell 1.88% after the announcement. » Więcej na de.investing.com